Sanofi-logo

For US Healthcare Professional use only.
The safety and efficacy of these investigational agents have not been established.
Chronic Spontaneous Urticaria

A Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Phase 2 Study of Rilzabrutinib Followed by an Open-label Extension Phase in Patients With Moderate-to-severe Chronic Spontaneous Urticaria Who Remain Symptomatic Despite the Use of H1-Antihistamine Treatment (RILECSU)

A Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Phase 2 Study of Rilzabrutinib Followed by an Open-label Extension Phase in Patients With Moderate-to-severe Chronic Spontaneous Urticaria Who Remain Symptomatic Despite the Use of H1-Antihistamine Treatment (RILECSU)
A Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Phase 2 Study of Rilzabrutinib Followed by an Open-label Extension Phase in Patients With Moderate-to-severe Chronic Spontaneous Urticaria Who Remain Symptomatic Despite the Use of H1-Antihistamine Treatment (RILECSU) Scan and Download Back

Privacy & Data Protection        Cookies Policy
Does not include study cards for clinical programs of dupilumab.

MAT-US-2401225 v1.0 - P Exp. Date: 02/12/2026
© 2024 Sanofi. All rights reserved.